Tevogen Bio, Inc. (NASDAQ: TVGNW) is a clinical-stage biotechnology company focused on the development and commercialization of off-the-shelf T-cell immunotherapies. Leveraging a proprietary platform for the rapid expansion of virus-specific T cells from healthy donors, the company aims to address both infectious diseases and cancer. Its lead programs include multi-virus-specific T-cell products for the treatment of respiratory pathogens and opportunistic infections in immunocompromised patients.
The company’s immunotherapy pipeline encompasses treatments for viral infections such as COVID-19, cytomegalovirus (CMV) and Epstein-Barr virus (EBV), as well as invasive fungal pathogens. In parallel, Tevogen is advancing allogeneic T-cell therapies engineered to recognize tumor-associated antigens, with preclinical efforts targeting hematological malignancies and solid tumors. These programs benefit from a streamlined manufacturing process designed to deliver off-the-shelf products at scale.
Founded in 2013 and headquartered in Houston, Texas, Tevogen Bio operates a dedicated cell-therapy manufacturing facility that supports both domestic and international clinical collaborations. The company has entered partnerships with academic institutions and government agencies to further validate its platform and to facilitate regulatory submissions. Tevogen’s management team combines expertise in immunology, cell therapy manufacturing and translational medicine, positioning the company to advance multiple assets through clinical development.
As a NASDAQ-listed public company, Tevogen Bio continues to expand its pipeline with the goal of delivering readily available T-cell therapies that can be administered without patient-specific manufacturing delays. Ongoing clinical trials and regulatory interactions seek to establish safety and efficacy across its lead indications and to create a foundation for broader commercial launch.
AI Generated. May Contain Errors.
MarketBeat All Access